We are immensely proud of our ATMP treatment for an extremely rare disease affecting very young children. It was therefore very important for us to identify a partner who had the right experience, knowledge and WDA licences with ATMP and cold chain categorisation for Europe and UK to who we could entrust the ownership of our ultra-cold chain product direct from the manufacturer to hospitals across Europe. Therismos with its EU based Ireland operation has partnered with us to perform this since the first launch of our ATMP and have reliably carried out the sales on our behalf ever since, being particularly supportive in finding solutions for importing to the UK and Sweden. Being able to trust a partner like Therismos has meant we could efficiently use our resources to focus more on the clinical aspects including new developments. It’s a model that works really well for us.
Latest News
We’re delighted to announce that Therismos has been appointed as the exclusive distributor for Canopy Growth Corporation’s range of Spectrum Therapeutic medical cannabis products in the UK and Channel Islands.
March 15, 2023
No Comments
